Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Lancet (London, England)
- Publicado em
- 12 abr 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial
Trong Toan Nguyen, Cheng-Hsun Chiu, Chien-Yu Lin, Nan-Chang Chiu, Po-Yen Chen, Thi Tuong Vy Le, Dang Ngan Le, An Han Duong, Van Luan Nguyen, Thi Nguyet Huynh et al.
Descritores MeSH
- Enterovirus A, Human
- Enterovirus Infections
- Enterovirus
- Double-Blind Method
- Vaccines, Inactivated
- Adjuvants, Immunologic
- Humans
- Infant
- Antibodies, Viral
- Child
Veja também
Estudos relacionados
- Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial
- Seroprevalence of coxsackievirus A6 and enterovirus A71 infection in humans: a systematic review and meta-analysis
- Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial
- Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial